{"id":"NCT01995201","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","officialTitle":"A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2015-07","completion":"2016-03","firstPosted":"2013-11-26","resultsPosted":"2018-01-26","lastUpdate":"2018-01-26"},"enrollment":401,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"DMARD","otherNames":[]},{"type":"DRUG","name":"methotrexate","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]},{"type":"DRUG","name":"tocilizumab [RoActemra/Actemra]","otherNames":[]}],"arms":[{"label":"Part 1: All patients","type":"EXPERIMENTAL"},{"label":"Part 2 A: Sustained clinical remission","type":"EXPERIMENTAL"},{"label":"Part 2 B: Low disease activity","type":"EXPERIMENTAL"}],"summary":"This multicenter, open-label study will evaluate the efficacy and safety of subcutaneously administered RoActemra/Actemra (tocilizumab) as monotherapy or in combination with methotrexate or other non-biologic DMARDs in patients with active rheumatoid arthritis and an inadequate response to non-biologic DMARDs or to one anti-TNF. In Phase 1, all patients will receive RoActemra/Actemra 162 mg subcutaneously (sc) weekly for Weeks 1 to 24, with or without methotrexate or other non-biologic DMARDs. For Part 2, patients who achieve sustained clinical DAS28-ESR remission at Weeks 20 and 24 will be randomized to receive RoActemra/Actemra 162 mg sc either weekly or every 2 weeks for Weeks 24 to 48, with or without methotrexate or other non-biologic DMARDs. Patients who do not achieve sustained clinical remission but achieve low disease activity (DAS-ESR \\</= 3.2) will continue the initial treatment of RoActemra/Actemra 162 mg sc weekly for Weeks 24 to 48, with or without methotrexate or other non-biologic DMARDs.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Clinical Remission, Disease Activity Scale 28 - Erythrocyte Sedimentation Rate <26 (DAS28-ESR <2.6) at Week 20 and Week 24","timeFrame":"Week 20 and Week 24","effectByArm":[{"arm":"Phase 1: Tocilizumab Monotherapy","deltaMin":48.4,"sd":null},{"arm":"Phase 1: Combination Therapy","deltaMin":52.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.5231"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":22},"locations":{"siteCount":53,"countries":["Ireland","Portugal","Spain"]},"refs":{"pmids":["31087542","30649524","29244149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":74},"commonTop":["Upper respiratory tract infection","Urinary tract infection","Transaminases increased","Neutropenia","Nausea"]}}